AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21969495
Drug: CAP (825
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP (825 mg/m2 orally twice daily, days 1 to 14)
Trial: 18819175
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (prophylactic agent) with an Active Response Rate (ARR) of 50%
Trial: 18819175
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with a Placebo Response Rate (PRR) of 25%
Trial: 16918593
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin (INH) administered preprandially using a metered-dose inhaler (MDI) for 4 weeks
Trial: 16918593
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (GLA) injected subcutaneously at bedtime for 4 weeks
Trial: 12600857
Drug: L-5-methyltetrahydrofolate (113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-methyltetrahydrofolate (113 microg)
Trial: 10987607
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous isosorbide-dinitrate (ISDN) 4 mg every 4 min (n = 20)
Trial: 10987607
Drug: BiPAP ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiPAP ventilation and standard dose nitrate therapy (n = 20)
Trial: 1333903
Drug: L-TAE with
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TAE with Farmorubicin (FARM)
Trial: 1333903
Drug: L-TAE with
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TAE with Adriamycin (ADR)
Trial: 6711269
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 0.5% mepivacaine with adrenaline (200 mg)
Trial: 6711269
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 1% mepivacaine with adrenaline (400 mg)
Trial: 6711269
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 1.5% mepivacaine with adrenaline (600 mg)
Trial: 31162191
Drug: XueBiJing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XueBiJing injection (100 mL, q12 hours)
Trial: 31162191
Drug: XueBiJing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XueBiJing injection
Trial: 28750059
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Trial: 28750059
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of reduced-glycerin 1% tenofovir (RG-TFV) gel
Trial: 28750059
Drug: RG-TFV gel
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-TFV gel applied before and after receptive anal intercourse (RAI)
Trial: 24906790
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU), n=17
Trial: 24282626
Drug: Gatifloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin (10 mg/kg/day in a single dose for 7 days)
Trial: 24282626
Drug: Ofloxacin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (20 mg/kg/day in two divided doses for 7 days)
Trial: 21954644
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g i.v. 3 times a day and amikacine 500 mg i.v. 2 times a day (Group 1A)
Trial: 21954644
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g i.v. bolus, then permanent infusion 3 g per day and amikacine 15 mg/kg per day once a day (Group 1B)
Trial: 19700988
Drug: PCEA (0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA (0.1% bupivacaine plus hydromorphone 10 mcg/mL at 8 mL/h plus bolus dosing)
Trial: 19700988
Drug: IV‐PCA (hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV‐PCA (hydromorphone 2 mcg/kg/h continuous infusion; 2 mcg/kg bolus dose)
Trial: 16916874
Drug: 1% chloramphenicol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chloramphenicol and 1% clotrimazole ointment
Trial: 16916874
Drug: 1% chloramphenicol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chloramphenicol and placebo ointment
Trial: 15675184
Drug: HGF plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGF plasmid DNA (three dose/regimens)
Trial: 9425843
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole in the night before operation
Trial: 8484550
Drug: Continuous supplemental
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous supplemental inspired oxygen by nasal catheters [4 L/min] (Oxygen Group, n = 52)
Trial: 3318443
Drug: S-adenosylmethionine (SAMe)
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosylmethionine (SAMe) 1,200 mg per day
Trial: 3318443
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg per day
Trial: 26100719
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus text messages timed to medication regimen
Trial: 19663111
Drug: Clindamycin-BP 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-BP 2.5% gel
Trial: 12324782
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gluconate and amoxicillin plus clavulanic acid
Trial: 12324782
Drug: 0.09% sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09% sterile saline solution
Trial: 580055
Drug: BAY g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY g 2821 (40 mg)
Trial: 580055
Drug: Etacrynic acid
RxNorm normalized name: Etacrynic acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etacrynic acid (50 mg)
Trial: 23964830
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tadalafil on alternate days
Trial: 23964830
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of statin a day
Trial: 23964830
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of tadalafil on alternate days and 10 mg of statin a day
Trial: 22668797
Drug: Cilengitide 500
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 500 mg administered intravenously twice weekly
Trial: 22668797
Drug: Cilengitide 2000
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2000 mg administered intravenously twice weekly
Trial: 11172529
Drug: Biological, psychological,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological, psychological, and psychosocial theories
Trial: 24274627
Drug: clinical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical management combined with pharmacotherapy
Trial: 18693158
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolaevulinate (MAL PDT)
Trial: 16725264
Drug: Glutamine granules
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine granules (0.5 g/kg/d for 14 days)
Trial: 14609903
Drug: Sucrose and
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose and oral tactile stimulation (with a pacifier or a bottle) and parental holding during immunization
Trial: 8993082
Drug: Family-focused psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused psychoeducational treatment
Trial: 6143471
Drug: Beta-adrenoceptor blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoceptor blocker (metoprolol)
Trial: 20739445
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement containing (n-3) fatty acids (2.0 g EPA + 0.9 g DHA/d)
Trial: 15705052
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g.d(‐1) x 5 d)
Trial: 12885709
Drug: Low-phytate bread
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-phytate bread fortified with zinc sulfate (60 mg elemental Zn/kg wheat flour)
Trial: 12885709
Drug: Higher-phytate porridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-phytate porridge fortified with zinc sulfate (60 mg elemental Zn/kg wheat flour)
Trial: 12885709
Drug: Higher-phytate porridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-phytate porridge fortified with zinc oxide (60 mg elemental Zn/kg wheat flour)
Trial: 6356145
Drug: Neutrons-only therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutrons-only therapy
Trial: 6356145
Drug: Neutron or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron or mixed-beam therapy
Trial: 22731794
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy group (higher frequency of follow-up)
Trial: 22731794
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy group (lower frequency of follow-up)
Trial: 19962986
Drug: Earlier-onset puberty
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Oncet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier-onset puberty (serum testosterone levels >= 2.5 ng/mL at 15 years old, n = 87)
Trial: 18396081
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection with EMG assistance
Trial: 18396081
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection without EMG assistance
Trial: 17121034
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) group with basic therapy and syndrome-differentiation dependent TCM treatment
Trial: 17121034
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (WM) group treated with non-steroidal anti-inflammatory drugs and slow-acting antirheumatic drug
Trial: 9349927
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 1.625 mg/day via pMDI
Trial: 9349927
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 1.60 mg/day via pMDI with integrated spacer
Trial: 26766637
Drug: 0.75% povidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% povidone iodine solution for at least 3 minutes
Trial: 25219351
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg BID for 3 days followed by topiramate 100 mg BID from days 4 to 10
Trial: 25219351
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg QD for 8 days followed by topiramate 96 mg BID from days 9 to 22
Trial: 25219351
Drug: Topiramate 96
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 96 mg BID alone for 11 days followed by pioglitazone 30 mg QD and topiramate 96 mg BID from days 12 to 22
Trial: 18019884
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (supervised yoga program meeting twice per week for 90 minutes)
Trial: 15841103
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement during leuprolide acetate treatment
Trial: 10495461
Drug: Bootstrap resampling
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bootstrap resampling method for bias correction in group sequential designs
Trial: 7743791
Drug: Normal values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal values of cardiac index (CI) 2.5 < or = CI < or = 3.5 L min‐1 m‐2
Trial: 7743791
Drug: Supranormal values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supranormal values of cardiac index (CI > or = 4.5 L min‐1 m‐2)
Trial: 17561792
Drug: Human regular
RxNorm normalized name: Human regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human regular insulin (Control)
Trial: 15708175
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (80 mg of caffeine)
Trial: 11998992
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 microg once-daily
Trial: 11998992
Drug: Ipratropium 40
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium 40 microg four-times daily
Trial: 10551290
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of dexamethasone sodium phosphate
Trial: 10551290
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of triamcinolone acetonide
Trial: 8703660
Drug: Azapropazone 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azapropazone 1200 mg
Trial: 21102210
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic continuous infusion device (pain pump) in addition to oral analgesics
Trial: 21102210
Drug: Oral analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics only
Trial: 21102210
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic continuous infusion device (pain pump)
Trial: 12139207
Drug: Lormetazepam 1
RxNorm normalized name: lormetazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 1 mg tablet
Trial: 8187029
Drug: 443c81 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 443c81 (5 ml of a 4 mg/ml solution nebulized) four times daily for 7 days
Trial: 8187029
Drug: 443c81 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 443c81 (5 ml of a 4 mg/ml solution nebulized)
Trial: 3251339
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous and oral doses of 50 mg of UDCA
Trial: 3251339
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of 25, 100, and 300 mg of UDCA
Trial: 31153789
Drug: Pilates group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates group 2 (twice a week)
Trial: 27804067
Drug: Constant-Activity-Rate (CA)
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant-Activity-Rate (CA) infusion
Trial: 27804067
Drug: Constant-Flow-Rate (CF)
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant-Flow-Rate (CF) infusion
Trial: 27281806
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron and folic acid (IFA) supplements (60 mg Fe and 2800 μg FA)
Trial: 27281806
Drug: Weekly multiple
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly multiple micronutrient (MM) supplements (same amount of FA and iron plus other MMs)
Trial: 27281806
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) supplements (2800 μg FA)
Trial: 20443499
Drug: RT01-based dose-volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT01-based dose-volume constraints
Trial: 20443499
Drug: CHHiP dose-volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHHiP dose-volume constraints
Trial: 20443499
Drug: Dose-volume constraints
RxNorm normalized name: Constrained Metal (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-volume constraints proposed by other researchers
Trial: 18560820
Drug: Lime powder
RxNorm normalized name: Lime
DrugBank: Lime (citrus) (DB10635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lime powder solution (Group 1)
Trial: 15986401
Drug: Nurse-driven cancer
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-driven cancer care intervention, monthly meetings for 6 months with an oncology nurse, using an interactive computer program.
Trial: 10475150
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 microg subcutaneous injections at 18:00 h and 23:00 h)
Trial: 10475150
Drug: Saline (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (subcutaneous injections at 18:00 h and 23:00 h)
Trial: 8611872
Drug: Conventional postoperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postoperative intravenous fluids
Trial: 2502417
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g cholestyramine
Trial: 6214264
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g cholestyramine
Trial: 6214264
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g cholestyramine
Trial: 6214264
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of cholestyramine
Trial: 31743169
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 µg/kg (D 1)
Trial: 31743169
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 µg/kg (D 0.5)
Trial: 31743169
Drug: Dexmedetomidine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.25 µg/kg (D 0.25)
Trial: 27852708
Drug: Aveeno lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aveeno lotion
Trial: 27852708
Drug: Diprobase cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprobase cream
Trial: 27852708
Drug: Doublebase gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublebase gel
Trial: 27852708
Drug: Hydromol ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromol ointment
Trial: 17409317
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (Losartan and Placebo)
Trial: 9726683
Drug: Ceftibuten (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten (9 mg/kg q.d. for 14 days)
Trial: 9726683
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (nasal saline drops allowed)
Trial: 8039152
Drug: Sequential tamoxifen/megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential tamoxifen/megestrol for 2 years
Trial: 8039152
Drug: High‐dose chemotherapy+autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose chemotherapy+autologous bone marrow transplantation
Trial: 8039152
Drug: CMF- or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF- or FEC-chemotherapy plus APD (pamidronate)
Trial: 30793734
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg with P2Y12 inhibitor
Trial: 30793734
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg with P2Y12 inhibitor
Trial: 27655276
Drug: Buccal oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal oxygenation via a modified 3.5‐mm Ring‐Adair‐Elwyn (RAE) tube
Trial: 19959920
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored intervention program consisting of physical and daily activities led by physiotherapists and occupational therapists for three months